RxDoctor Payments Data

Taylor Thorpe

Medical · Cleveland, OHNPI 1851993455

Payments from drug & device makers

$2,709in general payments, 2019–2025

Across 118 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$475
  • E.r. Squibb & Sons, L.L.C.$402
  • Alkermes, Inc.$375
  • Johnson & Johnson$365
  • Otsuka America Pharmaceutical, Inc.$323
  • Neurocrine Biosciences, Inc.$176
  • plus $593 from 7 others

What the payments were for

  • Food & beverage$2,48692%
  • Education$2238%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,709 in reported general payments places this provider in the 80th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$3,629
Medicare patients
16
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate79$231,437
Abilify MaintenaAripiprazole14$34,964
Paliperidone ErPaliperidone63$6,805
Clozapine15$1,231
Divalproex Sodium ErDivalproex Sodium15$1,092
Haloperidol Decanoate26$1,020
Aripiprazole38$952
Benztropine Mesylate49$934
Divalproex Sodium29$897
Olanzapine31$881
Doxepin Hcl14$746
Lurasidone Hcl13$589
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$555
Buspirone Hcl29$548
Risperidone20$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$365$231,43779 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$323$34,96414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 547 medical providers in Ohio.

Other medical in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →